VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

11025	Companies
241656	Keywords
170132	Articles
130105	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 09/13/2024 at 08:30, 2 years ago

Valneva Announces the Success of its Private Placement Raising approximately €60 Million
Valneva SE successfully raises approximately €60 million through a Private Placement, issuing 23,000,000 new ordinary shares. The funding will support the company's clinical programs and future growth, including the Shigella vaccine program

Private Placement Shareholders Funding Valneva SE Vaccine Program
BRIEF

published on 09/12/2024 at 22:10, 2 years ago

Valneva initiates a capital increase of 60 million euros

Euronext Paris Funding Capital Increase Valneva Vaccines
PRESS RELEASE

published on 09/12/2024 at 22:05, 2 years ago

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
Valneva announces private placement of ordinary shares for 60 million Euros to fund clinical and pre-clinical programs, commercialization activities, and general corporate purposes. Accelerated book-building process underway

Private Placement Ordinary Shares Valneva Clinical Programs Accelerated Book-building
BRIEF

published on 09/03/2024 at 07:05, 2 years ago

Valneva and Pfizer: new positive data on Lyme disease vaccine

Valneva Phase 2 Pfizer Lyme Vaccine Positive Data
PRESS RELEASE

published on 09/03/2024 at 07:00, 2 years ago

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Valneva and Pfizer announce positive Phase 2 booster results for Lyme disease vaccine candidate, VLA15-221, showing strong immune response and safety profile, advancing towards Phase 3 trials

Valneva Phase 2 Lyme Disease Vaccine Pfizer Immunogenicity
BRIEF

published on 08/30/2024 at 11:06, 2 years ago

Valneva SE Crosses Threshold

Voting Rights Stock Market Valneva SE Threshold Crossing Grimaud Group
BRIEF

published on 08/20/2024 at 16:06, 2 years ago

First Berlin Equity Research Reiterates Buy Rating for Valneva SE

Valneva Equity Research Market Undervaluation H1 Results Lyme Vaccine
PRESS RELEASE

published on 08/20/2024 at 16:01, 2 years ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE (ISIN: FR0004056851) with a BUY recommendation and EUR 8.60 price target. H1 product sales slightly below consensus but gross margin improving. Valneva maintains full-year guidance

First Berlin Equity Research Buy Recommendation Valneva SE EUR 8.60 Price Target H1 Product Sales
BRIEF

published on 08/13/2024 at 07:05, 2 years 1 month ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Financial Results Cash Position Revenue Guidance Valneva Vaccine Development
PRESS RELEASE

published on 08/13/2024 at 07:00, 2 years 1 month ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
Valneva reports first-half 2024 financial results as total revenues reach €70.8 million with net profit of €34.0 million. Company confirms full-year guidance and updates strategic pipeline expansion

Revenues Financial Results Net Profit Valneva Strategic Pipeline

Accesswire

Published on 09/19/2026 at 00:55, 6 hours 22 minutes ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 7 hours 27 minutes ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 9 hours 17 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 10 hours 42 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 16 hours 47 minutes ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/18/2026 at 18:45, 12 hours 32 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 12 hours 33 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 13 hours 4 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 13 hours 7 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 13 hours 10 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 12 hours 43 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 13 hours 32 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 13 hours 32 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 13 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 10 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE